Edwards Lifesciences Shows Improved Price Strength & IBD Rating Upgrade [Investor's Business Daily]
Repligen Corporation (RGEN)
Last repligen corporation earnings: 2/20 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
repligen.com/investors
Company Research
Source: Investors Business Daily
Related news 3/02/2020 On Monday, Repligen got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. This Week On IBD Live (Feb. 28) Stocks With Rising Relative Price Strength: Repligen Edwards Lifesciences Shows Strength With Jump In RS Rating Edwards Lifesciences Earns Composite Rating Upgrade Amid Stock Market Sell-Off, 4 Top Stocks To Watch Include Alibaba, Twitter And Uber Technologies This Medtech Giant Is Grappling To Stay In A Buy Zone On Mixed Earnings Uber Stock's New Buy Point Headlines These 4 Leaders In Or Near Buy Zones In Today's Stock Market Quidel Sees Composite Rating Climb To 97 Edwards Lifesciences ( EW ) saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 68 to 74. The IBD 50 stock is now considered extended and out of buy range after clearing a 195.10 buy point in a first-stage cup with handle . See if the stock forms a new chart pattern or follow-on buying
Show less
Read more
Impact Snapshot
Event Time:
RGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGEN alerts
High impacting Repligen Corporation news events
Weekly update
A roundup of the hottest topics
RGEN
News
- Biologics Conference 2025 Concludes Successfully, Setting New Benchmarks in Biopharmaceutical Innovation and Collaboration [Yahoo! Finance]Yahoo! Finance
- 3 Healthcare Stocks Skating on Thin Ice [Yahoo! Finance]Yahoo! Finance
- Repligen to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire
- https://seekingalpha.com/news/4405601-repligen-started-at-buy-by-td-cowen-limited-nih-exposure-cited [Seeking Alpha]Seeking Alpha
- Repligen Co. (NASDAQ: RGEN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $200.00 price target on the stock.MarketBeat
RGEN
Earnings
- 11/12/24 - Beat
RGEN
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form SCHEDULE
- 12/5/24 - Form 4
- RGEN's page on the SEC website